Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
Search Article 
Advanced search 
  Users Online: 1527 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
Year : 2011  |  Volume : 15  |  Issue : 4  |  Page : 294-297

Pioglitazone: Indian perspective

1 Department of Endocrinology, Regency Hospital, Kanpur, India
2 Department of Endocrinology, Bharti Hospital, Karnal, India

Correspondence Address:
Sanjay Kalra
Department of Endocrinology, Bharti Hospital and B.R.I.D.E, Karnal
Login to access the Email id

Source of Support: None, Conflict of Interest: None

PMID: 22029000

Rights and PermissionsRights and Permissions

Pioglitazone was approved in 1999 as an adjunct to exercise and diet to improve glycemic control in adults with type 2 diabetes mellitus, primarily by reducing insulin resistance. Beyond these effects on glucose metabolism, pioglitazone has positive effects on lipid metabolism, blood pressure, endothelial function, adiponectin, and C-reactive protein levels. These make pioglitazone treatment effective beyond glucose control. Pioglitazone generally has been viewed as a safer option for patients who warrant treatment with a thiazolidinedione-class drug. There has been some recent data on cancer incidence in patients on pioglitazone, which is currently being reviewed by drug regulatory authorities in the United States and in Europe. Given the benefits of pioglitazone, alone and in combination, it would be appropriate to continue judicious use of the drug in patients who may benefit from its use.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded591    
    Comments [Add]    

Recommend this journal